CD22 and congenital rubella syndrome: For instance, CD19/CD22 dual-target CAR-T constructs demonstrated significantly reduced grade 3–4 CRS (only one severe case among 16 patients) and no neurotoxicity, highlighting an improved safety profile linked to moderated cytokine kinetics [169].